The Journal of
Clinical Psychiatry

Neurology Seizures

Letter to the Editor October 15, 2003

Reply to Divalproex Versus Olanzapine in Mania

John M. Zajecka, MD

J Clin Psychiatry 2003;64(10):1266-1267

Article Abstract

Letter to the Editor

Reply to Divalproex Versus Olanzapine in Mania

Download Free PDF

This PDF is free for all visitors!

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 85 • 2024 • Number 4

Read the Current Issue

Meta-Analysis

Changes in Cognition in Patients With Schizophrenia

Systematic Review

Diagnostic Assessment via Telehealth vs Face-to-Face

Original Research

Prevalence, Correlates, and Burden of Subthreshold PTSD in US Veterans

Original Research

Bridge Symptoms Between Borderline Personality and PTSD

Original Research

Gepirone-ER and Sexual Function in Patients with MDD

Original Research

Medication Use and Lines of Treatment in Patients With Insomnia Disorder

View current Issue

Related Articles